EMA Authorised: Olanzapine Viatris (previously Olanzapine Mylan) (olanzapine) — Viatris Limited

View source ↗

Summary

The EMA has authorised Olanzapine Viatris for schizophrenia and bipolar disorder; the marketing authorization holder is Viatris Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Olanzapine Viatris (olanzapine)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Viatris Limited. Decision date: 07/01/2026